UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects

clinical-trails-etranacogene-dezaparvovec-cw
UniQure claims that preclinical data shows AAV5-based gene therapies such as etranacogene dezaparvovec may be clinically effective in patients with pre-existing antibodies to AAV5. Credit: anyaivanova / Shutterstock.